There are 2949 resources available
430P - Serial ctDNA (circulating tumour DNA) for detection of genomic changes during neoadjuvant chemoradiotherapy (NACRT) in locally advanced rectal cancer (LARC)
Presenter: Cha Len Lee
Session: E-Poster Display
Resources:
Abstract
431P - A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: Updated results of JCOG1007 study (iPACS)
Presenter: Yukihide Kanemitsu
Session: E-Poster Display
Resources:
Abstract
432P - Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database
Presenter: Demetris Papamichael
Session: E-Poster Display
Resources:
Abstract
434P - Impact of molecular markers status on treatment effects comparing EGFR and VEGF monoclonal antibodies (mAbs) in untreated metastatic colorectal cancer (mCRC): Pooled individual patient data (IPD) analysis of randomized trials from the ARCAD database
Presenter: Christos Karapetis
Session: E-Poster Display
Resources:
Abstract
433P - A phase Ib/II clinical trial of tolerability, safety and efficacy of regorafenib in combination with toripalimab (a PD-1 antibody) in patients with relapsed or metastatic colorectal cancer
Presenter: Feng Wang
Session: E-Poster Display
Resources:
Abstract
435P - Bevacizumab (bev) continuation with FOLFIRI or switch to aflibercept (afli) with FOLFIRI as second-line treatment (L2) after first line of FOLFOX-bev (L1) for metastatic colorectal cancer (mCRC): An AGEO multicenter study
Presenter: Cecile Torregrosa
Session: E-Poster Display
Resources:
Abstract
436P - Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer
Presenter: Daniel Ahn
Session: E-Poster Display
Resources:
Abstract
437P - Designing clinical profiles that influence the discordance of RAS mutations in blood and tissue: Sidedness and anatomical metastasis as factors of disagreement
Presenter: Elena Brozos-Vázquez
Session: E-Poster Display
Resources:
Abstract
438P - Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer: The RAMTAS trial of the German AIO
Presenter: Stefan Kasper
Session: E-Poster Display
Resources:
Abstract
439P - Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC)
Presenter: Do-Youn Oh
Session: E-Poster Display
Resources:
Abstract